Bitdeer Technologies Group vs Eli Lilly And Co — how do they compare? Bitdeer Technologies Group trades at $12.38 (market cap $3.01B), while Eli Lilly And Co trades at $1,153.75 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 342.2× Bitdeer Technologies Group's market cap, and Eli Lilly And Co pays a 0.6% dividend while Bitdeer Technologies Group pays none. Which is the better fit depends on your goals.
| BTDR | LLY | |
|---|---|---|
Market Cap | $3.01B | $1.03T |
Sector | Technology | Health |
52-Week High | $25.90 | $1.24K |
52-Week Low | $7.28 | $625.65 |
Enterprise Value | $4.77B | $1.07T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
BTDR trades at $12.13, down 8.73% over 24 hours, with technical indicators signaling a bearish trend. The stock shows strong analyst support with 9 out of 11 ratings as Buy and a consensus price target of $23.40, but fundamentals reveal challenges: negative net income margin of -26.96% and three consecutive quarterly earnings misses. Recent news highlights expansion into AI infrastructure, including a new $36 million manufacturing facility in Nevada and an AI cloud platform award in June 2026.
The outlook is mixed: bullish analyst sentiment and strategic growth in AI and mining infrastructure offer upside potential, but persistent losses, negative cash flow from operations, and high debt-to-asset ratio of 35.69% pose significant risks. Investors should weigh the company's expansion against its financial health and sector volatility.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Trailing returns across standard periods
Latest headlines on both assets
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →